Shenglan Huang

Shenglan Huang

Auto-generated profile, based on publicly available information

Shenglan Huang

Nanchang University Second Affiliated Hospital

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Neoplasma
Verified
Journal Article
Open access
YSY. Shen
Y. Shen
YWY. Wu
Y. Wu
MCMin Chen
Min Chen
Wenzhong ShenWenzhong Shen
Wenzhong Shen
SHS. Huang
S. Huang
XZXiaoping Zou
Xiaoping Zou
Effects of pantoprazole as a HIF-1α inhibitor on human gastric adenocarcinoma sgc-7901 cells

9 March 2022 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
LSLi-Ying Sun
Li-Ying Sun
JZJian Zhang
Jian Zhang
KWKai Wen
Kai Wen
SHShenglan Huang
Shenglan Huang
DLDan Li
Dan Li
JWJianbing Wu
Jianbing Wu
Background: Hepatocellular carcinoma (HCC) is a tumor with high morbidity and mortality worldwide. lysine acetylation regulators (LARs) dynamically regulate Lysine acetylation modification which plays an important regulatory role in cancer. Therefore, we aimed to explore the potential clinical prognostic value of LARs in HCC.Methods: Differentially expressed LARs in normal liver and HCC tissues were obtained from The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) datasets. To identify genes with prognostic value and establish the risk characteristics of LARs, consensus clustering was employed. We used univariate Cox regression survival analysis and LASSO Cox regression based on LARs to determine the independent prognostic signature of HCC. CIBERSORT and Gene Set Enrichment Analysis (GSEA) were used to estimate immune infiltration and functional enrichment analysis respectively. The expression of LAR was detected by Real-time quantitative polymerase chain reaction (RT-qPCR). statistical analyses were conducted using SPSS and R software.Results: In this study, the 33 LARs expression data and corresponding clinical information of HCC were obtained using TCGA and ICGC datasets. We found majority of the LARs were differentially expressed. Consensus cluster analysis was carried out based on the TCGA cohort, and three HCC subtypes (cluster 1, 2, and 3) were obtained. The LA3 subgroup had the worst clinical outcomes. Nine key LARs were identified to affect prognosis. The results showed that LARs signature has a strong independent prognostic value in HCC patients, whether in the training datasets or in the testing datasets. GSEA results showed that various tumor-related processes and pathways were abundant in the high-risk groups. RT-qPCR results showed that HAT1, HDAC1, HDAC2, HDAC4, and HDAC11 were highly expressed in HCC cells.Conclusion: Our results suggest that LARs play critical roles in HCC and are helpful for individual prognosis monitoring and clinical decision-making of HCC.

12 April 2021 in Research Square
Verified
Preprint
Open access
PDF file
SHShenglan Huang
Shenglan Huang
DLDan Li
Dan Li
LZLingLing Zhuang
LingLing Zhuang
LSLiying Sun
Liying Sun
JWJianbing Wu
Jianbing Wu
Introduction: Actin‐related protein 2/3 complex (Arp2/3) is a major actin nucleator containing seven subunits in humans, which has been widely reported that Arp2/3 plays an important role in promoting migration and invasion of various kinds of cancers. Nevertheless, the expression patterns and prognostic values of Arp2/3 subunits and the correlation between ARP2/3 subunits with immune infiltration in hepatocellular carcinoma remains unclear.Methods: TCGA-FPKM dataset, Oncomine, CCLE and UCSC Xena database was used to obtained mRNA expression and clinical information of Arp2/3 subunits in HCC. The Arp2/3 subunits differential expression in HCC tissues and cell lines was analyzed by utilizing the Perl 5.30.0 and R 4.0.4 software. The protein expression data of Arp2/3 subunits was obtained from The Human Protein Atlas (HPA). The prognostic value of each individual Arp2/3 subunits was identified by R 4.0.4 software. The association between the mRNA expressions of Arp2/3 members in HCC tissues with their clinicopathologic parameters was analyzed by UALCAN. The relevance between tumor immunocyte infiltration and the Arp2/3 complex members were determined by the TIMER 2.0 platform and GEPIA database. A gene set enrichment analysis (GSEA) was performed to explore the potential mechanism of Arp2/3 complex members in the carcinogenesis of HCC.Results:The results revealed that expression of Arp2/3 family members(ACTR2,ACTR3,ARPC1A, APRC1B,ARPC2,ARPC3,ARPC4, ARPC5, ARPC5L) were up-regulated in hepatocellular carcinoma (HCC). Moreover, higher protein expressions of of ACTR3, ARPC1A, ARPC1B, ARPC2 were found in HCC tissues compared with normal liver tissues. The higher expression of of Arp2/3 family members were significantly correlated with poor survival and cancer stages in HCC patients. Multivariate analysis also demonstrated that ACTR3, ARPC2 and ARPC5 were independent prognostic biomarkers of survival in HCC patients. Meanwhile, ACTR3, ARPC2 and ARPC5 in HCC has positive significant correlations with the infiltration of immune cells. The GSEA results indicated that Arp2/3 members significantly involve in multiple cancer-related pathways by which promoted development of HCC. Conclusions:Various analysis indicated that certain Arp2/3 complex subunits were noticeably upregulated and predicted worse survival in HCC, which may be applied as promising molecular targets for diagnosis and therapy of HCC in the future.

30 September 2021 in Research Square
Verified
Preprint
Open access
PDF file
SHShenglan Huang
Shenglan Huang
JZJian Zhang
Jian Zhang
DLDan Li
Dan Li
XLXiaolan Lai
Xiaolan Lai
LZLingling Zhuang
Lingling Zhuang
JWJianbing Wu
Jianbing Wu
Introduction: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with poor prognosis. Tumor microenvironment (TME) plays a vital role in the tumor progression of HCC. Thus, we aimed to analyze the association of TME with HCC prognosis, and construct an TME-related lncRNAs signature for predicting the prognosis of HCC patients.Methods: We firstly assessed the stromal/immune /Estimate scores within the HCC microenvironment using the ESTIMATE algorithm based on TCGA database, and its associations with survival and clinicopathological parameters were also analyzed. Then, different expression lncRNAs were filtered out according to immune/stromal scores. Cox regression was performed to built an TME-related lncRNAs risk signature. Kaplan–Meier analysis was carried out to explored the prognostic values of the risk signature. Furthermore, we explored the biological functions and immune microenvironment feathers in high- and low risk groups. Lastly, we probed the association of the risk signature with the treatment responses to immune checkpoint inhibitors (ICIs) in HCC by comparing the immunophenoscore (IPS).Results: Stromal/immune /Estimate scores of HCC patients were obtained based on the ESTIMATE algorithm. The Kaplan-Meier curve analysis showed the high stromal/immune/ Estimate scores were significantly associated with better prognosis of the HCC patients. Then, six TME-related lncRNAs were screened for constructing the prognosis model. Kaplan-Meier survival curves suggested that HCC patients in high-risk group had worse prognosis than those with low-risk. ROC curve and Cox regression analyses demonstrated the signature could predict HCC survival exactly and independently. Function enrichment analysis revealed that some tumor- and immune-related pathways associated with HCC tumorigenesis and progression might be activated in high-risk group. We also discovered that some immune cells, which were beneficial to enhance immune responses towards cancer, were remarkably upregulated in low-risk group. Besides, there was closely correlation of immune checkmate inhibitors (ICIs) with the risk signature and the signature can be used to predict treatment response of ICIs.Conclusions: We analyzed the impact of the tumor microenvironment scores on the prognosis of patients with HCC. A novel TME-related prognostic risk signature was established, which may improve prognostic predictive accuracy and guide individualized immunotherapy for HCC patients.